Recent Updates
Recently added Catalysts
CRL Positive Sentiment

Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing

Thursday, August 20, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Charles River Laboratories is collaborating with Medigen Vaccine Biologics Corp. to advance the development of a next-generation multivalent enterovirus vaccine. This partnership will utilize Charles River's advanced analytical platforms, including Next-Generation Sequencing, to aid in the characterization and validation of the virus seed bank. The collaboration aims to enhance the Chemistry, Manufacturing, and Controls activities for the vaccine.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration between Charles River and Medigen is promising.
  • Use of advanced analytical platforms enhances vaccine development.
  • Next-Generation Sequencing will support critical CMC activities.

Full Press Release Details

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC’s next-generation multivalent

Frequently Asked Questions

What is the focus of the collaboration between CRL and Medigen?

The collaboration focuses on the development of a next-generation multivalent enterovirus vaccine.

What technology will Charles River use in this partnership?

Charles River will use Next-Generation Sequencing to support the vaccine development.

What are CMC activities in vaccine development?

CMC activities refer to Chemistry, Manufacturing, and Controls essential for vaccine production.

Who is Medigen Vaccine Biologics Corp?

Medigen Vaccine Biologics Corp. is a company focused on vaccine development.

ShareAdd on Google
Tags: CRL Viatris Investor Conferences Healthcare Charles River Laboratories Medigen Vaccine Biologics Next-Generation Sequencing multivalent vaccine enterovirus
Last updated: Aug 20, 2026

Biotech snapshot

Cash runway
$241M liquidity · $0M/mo burn
Low dilution risk